Investigational New Drug

CFDA accepts WuXi-MedImmune’s IND for new mAb

CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis.